Trial Profile
Phase 1 Trial of Oral Karenitecin in Patients With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 May 2021
Price :
$35
*
At a glance
- Drugs Cositecan (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors BioNumerik Pharmaceuticals
- 22 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Jun 2011 Planned end date changed from 1 Jun 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.